Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity.
Reports Buy online from $3500
Reports Buy online from $3500
Diabetes Market to 2016 - Biguanides and Insulin Analogs to be the Largest Selling Anti-Diabetic Drugs
GBI Research’s new report, “Diabetes Market to 2016 - Biguanides and Insulin Analogs to be the Largest Selling Anti-Diabetic Drugs”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global diabetes therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Reports Buy online from $3500
Reports Buy online from $3500
Neutropenia- Pipeline Assessment and Market Forecasts to 2017
GlobalData, the industry analysis specialist, has released a new report, “Neutropenia - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global neutropenia market. The report identifies the key trends shaping and driving the global neutropenia market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global neutropenia sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimated that the global neutropenia market was valued at $5.3 billion in 2009 and forecasts it to grow by 0.8% annually for the next eight years. This lower growth rate between the years 2009-2017 as compared to the year 2001-2009 is because of the expiry of the patents for Neulasta and Neupogen. GlobalData determined that the global neutropenia market is moderately served by the current product options and significant scope is available to new entrants that can capture value from underserved segments. Designing highly efficacious products that will encourage physician compliance is one of key challenges of this market and could provide a significant market share for any company achieving this.
GlobalData found that the global neutropenia market is highly competitive. The pipeline is considered to be strong because it consists of major promising drugs that will become blockbuster drugs in the coming years. These pipeline molecules also have improved efficacy and safety profiles over the currently marketed products, which means that they may meet patients’ and physicians’ expectations. The unmet need in the neutropenia market is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and efficacy profiles.
Reports Buy online from $2000
Reports Buy online from $2000
Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
GBI Research, the leading business intelligence provider, has released its latest report, “Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics” that provides key data, information and analysis of the major trends and issues in Personalized Medicine Market. The report provides a comprehensive insight into the role of Human Genomics and Proteomics to challenge traditional therapeutics. The report also provides a detailed analysis of market characterization of personalized medicine market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the patent landscape for human genomics and proteomics and provides comprehensive analysis.
Reports Buy online from $3500
Reports Buy online from $3500
Alzheimer’s Disease - Pipeline Assessment and Market Forecasts to 2017
GlobalData, the industry analysis specialist, has released its new report, “Alzheimer’s Disease - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Alzheimer’s disease market. The report identifies the key trends shaping and driving the global Alzheimer’s disease market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Alzheimer’s disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData has estimated the global Alzheimer’s disease therapeutics market to be valued at $7.1 billion in 2009. It is expected to decline to $5.2 billion with a Compound Annual Growth Rate (CAGR) of (4%) by 2017. The market structure is projected to change in the near future following the patent expiry of the leading drugs in next 2-3 years. Aricept patent expires in November 2010, Namenda’s (Forest) patent is set to expire in April 2015. There is a high unmet need in the current Alzheimer’s disease market in terms of both safety and efficacy profile
Reports Buy online from $2000
Reports Buy online from $2000
Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) - Pipeline Assessment and Market Forecasts to 2017
GlobalData, the industry analysis specialist, has released its new report, “Amyotrophic Lateral Sclerosis (ALS) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global ALS market. The report identifies the key trends shaping and driving the global ALS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ALS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global Amyotrophic Lateral Sclerosis (ALS) therapeutics market was valued at $174m in 2009. It is expected to grow to $234m at a Compound Annual Growth Rate (CAGR) of 3.8% by 2017. This slow growth is attributed to the patent expiry of Rilutek in 2012, which is the only approved drug in the market for the treatment of ALS. The etiology of ALS is not known, which poses significant challenges for prospective market entrants. The ageing population and the orphan drug status of the pipeline molecules will be the key drivers of this market.
Reports Buy online from $2000
Reports Buy online from $2000
Anemia - Pipeline Assessment and Market Forecasts to 2017
GlobalData, the industry analysis specialist, has released its new report, “Anemia - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Anemia market. The report identifies the key trends shaping and driving the global Anemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anemia sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData valued the anemia market in 2009 at $10.4 billion, indicating a CAGR of 7.4% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. The majority of these therapies were launched between 2001 and 2007 and as a result market growth was pronounced in that period. In 2007, safety concerns over the use of ESAs surfaced and this has led to a decline in sales of the drugs. Since then, growth in the anemia market has been declining. Between 2009 and 2017, the market is expected to decline further as there are no key promising therapies expected to enter the anemia market. Furthermore, biosimilars of ESAs have already entered the European market and are expected to enter the US market between 2009 and 2017. This factor is also expected to restrain the growth of the market.
Reports Buy online from $2000
Reports Buy online from $2000
Bipolar Disorder - Drug Pipeline Assessment and Market Forecasts to 2017
GlobalData, the industry analysis specialist, has released its new report, “Bipolar Disorder - Drug Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Bipolar Disorder market. The report identifies the key trends shaping and driving the global Bipolar Disorder market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Bipolar Disorder sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global Bipolar Disorder market was valued at $4.4 billion in 2009 and is forecast to decline by 10% annually for the next seven years to reach $1.9 billion by 2017. This modest decline in the forecast is primarily attributed to the patent expiry of all the major marketed products, the availability of the generic versions of those products, and the strong competition in the market. The Bipolar Disorder market is primarily formed of generic and off-label drugs and has very few approved drugs which fall in the major therapeutic categories such as Dopamine and Serotonin Antagonist and Sodium and calcium channel inhibitors.
Reports Buy online from $2000
Reports Buy online from $2000
Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016
GlobalData, the industry analysis specialist’s new report, “Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global chronic kidney disease market. The report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
Reports Buy online from $2000
Reports Buy online from $2000
Colorectal Cancer - UK Drug Forecasts and Treatment Analysis to 2020
GlobalData, the industry analysis specialist, has released its new report, “Colorectal Cancer - UK Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the UK colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the UK colorectal cancer therapeutics market. It analyses the treatment usage patterns in the UK colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the UK colorectal cancer therapeutics market, highlighting the opportunity for future players.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Reports Buy online from $5000
Reports Buy online from $5000
